Is humoral and cellular response to SARS-CoV-2 vaccine modified by DMT in patients with multiple sclerosis and other autoimmune diseases?
Zabalza A, Arrambide G, Otero-Romero S, Pappolla A, Tagliani P, López-Maza S, Cárdenas-Robledo S, Esperalba J, Fernández-Naval C, Martínez-Gallo M, Castillo M, Bonastre M, Resina-Salles M, Bertran J, Rodriguez-Barranco M, Carbonell-Mirabent P, Gonzalez M, Merchan M, Quiroga-Varela A, Miguela A, Gómez I, Álvarez G, Robles R, Perez Del Campo D, Queralt X, Soler MJ, Agraz I, Martinez-Valle F, Rodríguez-Acevedo B, Midaglia L, Vidal-Jordana Á, Cobo-Calvo Á, Tur C, Galan I, Castillo J, Río J, Espejo C, Comabella M, Nos C, Sastre-Garriga J, Ramió-Torrentà L, Tintoré M, Montalban X.
Zabalza A, et al. Among authors: rodriguez acevedo b, rodriguez barranco m.
Mult Scler. 2022 Jun;28(7):1138-1145. doi: 10.1177/13524585221089540. Epub 2022 Apr 27.
Mult Scler. 2022.
PMID: 35475363